Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucorafusp alfa
- Development stage
- Phase 2
- Lead developer
- Bicara Therapeutics
- Modality
- Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Lucorafusp alfa (AK130) is a first-in-class bifunctional antibody fusion protein developed by Akeso Inc. It consists of an anti-TIGIT monoclonal antibody fused to the extracellular domain of human transforming growth factor-β receptor II (TGFβ-RII). This dual-targeting approach aims to overcome immune evasion in the tumor microenvironment by simultaneously blocking the TIGIT-CD155 inhibitory pathway (reinvigorating CD8+ T cells and NK cells) and neutralizing TGF-β signaling (reducing immunosuppression and fibrosis). It is currently being evaluated in clinical trials for advanced solid tumors, including hepatocellular carcinoma and pancreatic cancer, both as a monotherapy and in combination with other immunotherapies like ivonescimab.
- Other names
- AK130AK-130AK 130TIGIT/TGF-β bifunctional fusion protein
02
Targets
TIGIT (T cell immunoreceptor with Ig and ITIM domains)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on lucorafusp alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucorafusp alfa.